Biotron Limited Release: Potential Eradication Of HIV Resevoirs Data Published
• Phase1b/2a trial data shows BIT225 has potential to eradicate important virus reservoirs and may provide additional health benefits.
• Key data from Biotron’s trial published in prestigious international scientific journal.
The Directors of Biotron Limited (‘Biotron’) are pleased to advise that a manuscript containing data from its key trial of BIT225 in HIV-1-infected subjects has been published in a prestigious international scientific journal.
The peer-reviewed paper, entitled “A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection” was published as advance access on 29 November 2015 in the Journal of Antimicrobial Chemotherapy.
As previously advised to the market, this clinical trial demonstrated that BIT225 can target and reduce levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. These reservoirs exist even in patients undergoing treatment with current antiretroviral drugs, and are responsible for ongoing cycles of reseeding HIV-1 infection.
The study also indicated that BIT225 may impact on immune activation. Immune activation is responsible for a number of ongoing health issues in these patients and treatment strategies are needed to prevent development of associated disorders which include accelerated aging and neurological dysfunction.
Biotron anticipates progressing its HIV program into a Phase 2 trial of BIT225 in combination with current antiretroviral drugs during the first half of 2016.
A copy of the manuscript can be viewed at the following link: http://bit.ly/1YGp64o
About Biotron
Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.
• Key data from Biotron’s trial published in prestigious international scientific journal.
The Directors of Biotron Limited (‘Biotron’) are pleased to advise that a manuscript containing data from its key trial of BIT225 in HIV-1-infected subjects has been published in a prestigious international scientific journal.
The peer-reviewed paper, entitled “A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection” was published as advance access on 29 November 2015 in the Journal of Antimicrobial Chemotherapy.
As previously advised to the market, this clinical trial demonstrated that BIT225 can target and reduce levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. These reservoirs exist even in patients undergoing treatment with current antiretroviral drugs, and are responsible for ongoing cycles of reseeding HIV-1 infection.
The study also indicated that BIT225 may impact on immune activation. Immune activation is responsible for a number of ongoing health issues in these patients and treatment strategies are needed to prevent development of associated disorders which include accelerated aging and neurological dysfunction.
Biotron anticipates progressing its HIV program into a Phase 2 trial of BIT225 in combination with current antiretroviral drugs during the first half of 2016.
A copy of the manuscript can be viewed at the following link: http://bit.ly/1YGp64o
About Biotron
Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.